Protein Kinase C Inhibitors Reduce SARS-CoV-2 Replication in Cultured Cells
Changbai Huang, Fei Feng, Yongxia Shi, Wenhui Li, Ziqiao Wang, Yunkai Zhu, Shuai Yuan, Dandan Hu, Jun Dai, Qiqi Jiang, Rong Zhang, Chao Liu, Ping Zhang
Abstract
There is an urgent need for effective therapeutic drugs to control the pandemic caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). We found that several inhibitors of protein kinases C (PKCs) dramatically decrease the replication of SARS-CoV-2 in cultured cells. These PKC inhibitors interfere with an early step of viral infection. Therefore, the rapid and prominent antiviral effect of PKC inhibitors underscores that they are promising antiviral agents and suggests that PKCs are important host factors involved in infection by SARS-CoV-2.
Topics & Concepts
KinasePandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyReplication (statistics)CoronavirusViral replication2019-20 coronavirus outbreakBiologyCoronavirus disease 2019 (COVID-19)MedicineVirusCell biologyInternal medicineDiseaseOutbreakInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVitamin C and Antioxidants Research